Currently immune checkpoints blockade therapies, such as; anti-programmed death-ligand 1 (anti-PD-L1) and anti- programmed death-ligand 1 (anti-PD-1), present promising anti-tumor efficacy for several types of solid tumors. This evidence concerns the gene CD274 and neoplasm.